Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis.

Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T.

J Gastroenterol Hepatol. 2019 Aug 8. doi: 10.1111/jgh.14825. [Epub ahead of print]

PMID:
31397010
2.

Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.

Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A.

World J Gastroenterol. 2015 Mar 21;21(11):3282-90. doi: 10.3748/wjg.v21.i11.3282.

3.

Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.

Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2019 Apr 11;25(5):945-954. doi: 10.1093/ibd/izy322.

PMID:
30329067
4.

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.

J Manag Care Spec Pharm. 2017 Aug;23(8):859-867. doi: 10.18553/jmcp.2017.16272. Epub 2017 Mar 15.

5.

Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.

Targownik LE, Tennakoon A, Leung S, Lix LM, Nugent Z, Singh H, Bernstein CN.

Inflamm Bowel Dis. 2017 Mar;23(3):409-420. doi: 10.1097/MIB.0000000000001025.

PMID:
28221250
6.

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427. doi: 10.1093/ibd/izz001.

PMID:
30839057
7.

Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.

Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1218-1225.e7. doi: 10.1016/j.cgh.2016.11.024. Epub 2016 Nov 29.

8.

Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.

Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS; PRO-KIIDS Research Group.

Gastroenterology. 2014 Feb;146(2):383-91. doi: 10.1053/j.gastro.2013.10.027. Epub 2013 Oct 23.

PMID:
24162032
9.

A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.

Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S.

Adv Ther. 2016 Nov;33(11):1947-1963. Epub 2016 Sep 23.

10.

Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.

Lee MY, Shin JY, Park SY, Kim D, Cha HS, Lee EK.

Semin Arthritis Rheum. 2018 Feb;47(4):485-491. doi: 10.1016/j.semarthrit.2017.08.007. Epub 2017 Aug 31.

PMID:
28939234
11.

The impact of biological interventions for ulcerative colitis on health-related quality of life.

LeBlanc K, Mosli MH, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD008655. doi: 10.1002/14651858.CD008655.pub3. Review.

PMID:
26393522
12.

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265.

PMID:
25389599
13.

TNFα-Inhibitors in Inflammatory Bowel Disease [Internet].

Ringerike T, Elvsaas IKØ, Coll P, Lundin KEA, Movik E, Gjertsen MK.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Dec.

14.

Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.

Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.

J Crohns Colitis. 2016 May;10(5):516-24. doi: 10.1093/ecco-jcc/jjw008. Epub 2016 Jan 22.

15.

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.

Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I.

Dig Dis Sci. 2017 Feb;62(2):481-490. doi: 10.1007/s10620-016-4398-5. Epub 2016 Dec 19.

PMID:
27995400
16.

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

Gies N, Kroeker KI, Wong K, Fedorak RN.

Aliment Pharmacol Ther. 2010 Aug;32(4):522-8. doi: 10.1111/j.1365-2036.2010.04380.x. Epub 2010 May 25.

17.

Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.

Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR.

Arthritis Care Res (Hoboken). 2015 May;67(5):624-32. doi: 10.1002/acr.22510.

18.

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

Abraham NS, Richardson P, Castillo D, Kane SV.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1281-7. doi: 10.1016/j.cgh.2013.06.004. Epub 2013 Jun 19.

PMID:
23792295
20.

Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD.

Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN.

Am J Gastroenterol. 2018 Aug;113(8):1206-1216. doi: 10.1038/s41395-018-0108-6. Epub 2018 Jun 21.

PMID:
29925912

Supplemental Content

Support Center